Histologic comparison of regeneration in human intrabony defects when osteogenin is combined with demineralized freeze-dried bone allograft and with purified bovine collagen.
A bone-inductive protein, osteogenin, has been isolated from long bones of humans and offers promise as a grafting material. Studies, however, suggest that osteogenin must be combined with a bone-derived matrix in order to initiate bone differentiation. The purpose of this study was to determine if osteogenin combined with demineralized freeze dried bone allograft (DFDBA), a bone-derived matrix, and with a bovine tendon-derived matrix will enhanced regeneration of intrabony defects in humans. The tendon-derived matrix and DFDBA used alone served as controls. The ability of each material to form a new attachment apparatus was evaluated independently in submerged and nonsubmerged environments in 2 patient populations. Lymphocyte testing was performed to assess development of an immune reaction to osteogenin. The most apical level of calculus on the root served as the histologic reference point to measure regeneration. Biopsies were obtained at 6 months and regeneration was measured histomorphometrically by 2 blinded evaluators. Serial sections from 36 submerged defects in 8 patients and 50 nonsubmerged defects in 6 patients were submitted for statistical analysis. Mean results indicate that osteogenin combined with DFDBA significantly enhanced regeneration of a new attachment apparatus and component tissues in a submerged environment. DFDBA plus osteogenin and DFDBA alone formed significantly more new attachment apparatus and component tissues than either the tendon-derived matrix plus osteogenin or the tendon-derived matrix alone in both submerged and nonsubmerged environments. There were no significant differences between the tendon-derived matrix plus osteogenin and the tendon-derived matrix alone in either the submerged or nonsubmerged environment. Osteogenin does not impair normal lymphocyte blastogenesis at 6 months postsurgical challenge.
Bowers
G
G
Department of Periodontics, University of Maryland, Baltimore College of Dental Surgery.
Felton
F
F
Middleton
C
C
Glynn
D
D
Sharp
S
S
Mellonig
J
J
Corio
R
R
Emerson
J
J
Park
S
S
Suzuki
J
J
Ma
S
S
Romberg
E
E
Reddi
A H
AH
D016301:Alveolar Bone Loss / Q000473:pathology / Q000601:surgery*; D000539:Alveolar Process / Q000473:pathology*; D000818:Animals; D000844:Ankylosis / Q000473:pathology; D001857:Bone Matrix / Q000473:pathology; D055398:Bone Morphogenetic Protein 3; D019485:Bone Morphogenetic Proteins; D001861:Bone Regeneration / Q000187:drug effects; D016025:Bone Transplantation / Q000379:methods* / Q000473:pathology; D002417:Cattle; D003094:Collagen / Q000627:therapeutic use*; D003648:Decalcification Technique; D003739:Dental Cementum / Q000473:pathology; D005612:Freeze Drying; D006133:Growth Substances / Q000627:therapeutic use*; D006801:Humans; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000473:pathology; D010519:Periodontium / Q000473:pathology; D011506:Proteins / Q000627:therapeutic use*; D012391:Root Resorption / Q000473:pathology; D013524:Surgical Flaps
C525757:BMP3 protein, human; D055398:Bone Morphogenetic Protein 3; D019485:Bone Morphogenetic Proteins; D006133:Growth Substances; D011506:Proteins; D003094:Collagen